BSD gets breast cancer therapy patent from Duke:
This article was originally published in Clinica
BSD Medical has signed an exclusive patent licence agreement for rights to Duke University's hyperthermia treatment for primary breast cancer. The Salt Lake City, Utah-based firm intends to integrate the technology with its current BSD-2000 and BSD-500 hyperthermia systems. The treatment will be used to complement radiation therapy, chemotherapy and heat-released, targeted liposome drug delivery. BSD claims that the potential to treat breast cancer with hyperthermia therapy has been boosted by trials at the Durham, North Carolina university. Studies have shown that patients receiving radiation therapy in conjunction with hyperthermia have a greater chance of complete response compared with those receiving radiotherapy alone.